| Literature DB >> 31438594 |
Anna Palubicka1,2, Radoslaw Jaworski3, Marcin Wekwejt4, Beata Swieczko-Zurek4, Michal Pikula5, Janusz Jaskiewicz2, Jacek Zielinski2.
Abstract
Background andEntities:
Keywords: breast implants; breast surgery; complications; surgical site infection
Mesh:
Substances:
Year: 2019 PMID: 31438594 PMCID: PMC6780406 DOI: 10.3390/medicina55090512
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Surgical site infection in breast cancer patients who underwent breast surgery at the Department of Surgical Oncology, Medical University of Gdansk in Poland in 2012–2016.
| Classic Breast Surgery | Breast-Conserving Surgery | Breast Reconstruction via the TRAM Flap Method | Subcutaneous Amputation with Simultaneous Reconstruction | ||
|---|---|---|---|---|---|
| All SSI | 46 (5.3%) | 48 (4.8%) | 8 (14.3%) | 30 (14.6%) | <0.001 |
| Early SSI | 34 (3.9%) | 31 (3.1%) | 4 (7.1%) | 17 (8.3%) | 0.004 |
| Late SSI | 12 (1.4%) | 17 (1.7%) | 4 (7.1%) | 13 (6.3%) | <0.001 |
SSI, surgical site infection; TRAM, transverse rectus abdominis muscle.
Figure 1Microorganisms responsible for surgical site infection (SSI) in patients who underwent breast surgery (number; percentages). MSSA, methicillin-susceptible Staphylococcus aureus; CNS, coagulase-negative Staphylococcus.
Microorganisms responsible for surgical site infection in breast cancer patients who underwent breast surgery at the Department of Surgical Oncology, Medical University of Gdansk in Poland in 2012–2016.
| Classic Breast Surgery | Breast-Conserving Surgery | Breast Reconstruction via the TRAM Flap Method | Subcutaneous Amputation with Simultaneous Reconstruction | ||
|---|---|---|---|---|---|
| MSSA | 22 (47.83%) | 16 (33.33%) | 3 (37.50%) | 11 (36.67%) | 0.529 |
| CNS | 7 (15.22%) | 10 (20.83%) | 0 (0.00%) | 6 (20.00%) | 0.499 |
| 3 (6.52%) | 4 (8.33%) | 1 (12.50%) | 1 (3.33%) | 0.763 | |
|
| 5 (10.87%) | 4 (8.33%) | 4 (50.00%) | 4 (13.33%) | 0.012 |
|
| 13 (28.26%) | 7 (14.58%) | 0 (0.00%) | 1 (3.33%) | 0.016 |
|
| 6 (13.04%) | 3 (6.25%) | 1 (12.50%) | 1 (3.33%) | 0.428 |
| Anaerobes | 3 (6.52%) | 4 (8.33%) | 0 (0.00%) | 0 (0.00%) | 0.370 |
MSSA, methicillin-susceptible Staphylococcus aureus; CNS, coagulase-negative Staphylococcus; TRAM, transverse rectus abdominis muscle.
Antibiotic susceptibility of Staphylococcus, Streptococcus spp. and Gram-negative bacilli strains isolated from breast cancer patients with surgical site infection at the Department of Surgical Oncology, Medical University of Gdansk in Poland in 2012–2016.
| Strains | ||||||||
|---|---|---|---|---|---|---|---|---|
|
| Coagulase-negative |
|
| Anaerobes | ||||
| Number of Strains | 52 | 23 | 17 | 9 | 21 | 11 | 7 | |
| Antibiotics | PE | 0% | 0% | 100% | 100% | --------- | --------- | 100% |
| MET | 100% | 78% | --------- | --------- | --------- | --------- | --------- | |
| GE | 100% | 100% | --------- | --------- | --------- | --------- | --------- | |
| GE High | --------- | --------- | 100% | --------- | --------- | --------- | --------- | |
| S High | --------- | --------- | 100% | --------- | --------- | --------- | --------- | |
| TYG | --------- | --------- | 100% | 100% | --------- | --------- | --------- | |
| TEI | --------- | --------- | 100% | 100% | --------- | --------- | --------- | |
| AN | 100% | 100% | --------- | --------- | 100% | 100% | --------- | |
| E | 89% | 78% | nr | 89% | --------- | --------- | --------- | |
| CC | 89% | 78% | nr | --------- | --------- | --------- | 43% | |
| SXT | 100% | 91% | nr | --------- | 91% | 100% | --------- | |
| CIP | 98% | 91% | 87% | 100% | 96% | 100% | --------- | |
| VA | 100% | 100% | 100% | 100% | --------- | --------- | --------- | |
| LZD | 100% | 100% | 100% | 100% | --------- | --------- | --------- | |
| AM | 100% | 78% | 100% | 100% | 26% | --------- | 100% | |
| AMC | 100% | 78% | 100% | 100% | 26% | --------- | 100% | |
| CXM | 100% | 78% | nr | 100% | 96% | --------- | --------- | |
| CTX | 100% | 78% | nr | 100% | 96% | 88% | --------- | |
| CAZ | 100% | 78% | nr | 100% | 96% | 88% | --------- | |
| IPM | 100% | 78% | 100% | 100% | 100% | 100% | --------- | |
| MEM | 100% | 78% | 100% | 100% | 100% | 100% | --------- | |
| MTZ | --------- | --------- | --------- | --------- | --------- | --------- | 100% | |
---------, not applicable/not tested; nr, natural resistance; PE, penicillin; MET, methicillin; GE, gentamicin; AN, amikacin; E, erythromycin; CC, clindamycin; SXT, trimethoprim/sulfamethoxazole; CIP, ciprofloxacin; VA, vancomycin; LZD, linezolid; GE High, high concentration of gentamicin; S High, high concentration of streptomycin; TYG, tigecycline; TEI, teicoplanin; AM, ampicillin; AMC, amoxicillin/clavulanic acid; CXM, cefuroxime; CTX, cefotaxime; CAZ, ceftazidime; IPM, imipenem; MEM, meropenem; MTZ, metronidazole.